Key Takeaways STE's Q1 EPS estimate of $2.32 suggests 14.3% growth from the year-ago quarter.STE's Healthcare and AST segments are expected to post revenue gains of 5.1% and 6.3%, respectively.STE's Life Sciences sales may rise 5.5% as mix, pricing, and divestiture aid margins despite capital softness.STERIS plc (STE) is scheduled to release first-quarter fiscal 2026 results on Aug. 7, after market close. In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.74, which surp ...